$2.170
+0.041 (+1.88%)At close
EDSA News
EDSA Events
Edesa Biotech Receives FDA Approval for EB06 Clinical Study
Edesa Biotech reported that the FDA has cleared the company's investigational new drug, or IND, application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the United States. Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter. Edesa anticipates that topline data will be available fourth quarter 2027.
Edesa Biotech Commences Underwritten Public Offering of Common Shares
Edesa Biotech announced that it has commenced an underwritten public offering of its common shares and accompanying common share warrants to purchase common shares. All common shares, pre-funded warrants and accompanying common share warrants are being offered by Edesa. Edesa intends to use the net proceeds from the proposed offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses. Guggenheim Securities is acting as the sole book-running manager for the proposed offering.
Edesa Biotech Files to Sell 729,241 Common Shares
Edesa Biotech files to sell 729,241 common shares for holders
Edesa Biotech Enters Securities Purchase Agreement for $3.5M Financing
Edesa Biotech announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $3.5M to the company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's CEO and healthcare-focused investors. The PIPE is expected to close on or about June 15, subject to the satisfaction of customary closing conditions. In the PIPE, the company is selling an aggregate of 729,241 common shares, at a purchase price of $4.69 per common share for investors and $5.21 per common share for Edesa's CEO.
Edesa Biotech Trading Halted Due to Volatility
Edesa Biotech Inc trading halted, volatility trading pause
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.